A randomized, double-blind, phase III study comparing two doses of erlotinib for second-line treatment of current smokers with advanced non-small-cell lung cancer (CurrentS)

Egbert F. Smit, Yi-Long Wu, Radj Gervais, Caicun Zhou, Enriqueta Felip, Jifeng Feng, Salih Zeki Guclu, Mathias Hoiczyk, Elena Dorokhova, Ulrich Freudensprung, Susan Grange, Pablo Diego Perez-Moreno, Lada Mitchell, Martin Reck

Research output: Contribution to journalArticleAcademicpeer-review

Original languageEnglish
Pages (from-to)94-101
JournalLung Cancer
Publication statusPublished - Sep 2016

Cite this